FSTL3 and hepatocellular carcinoma: We further validated the aberrant expression of FSTL3 in HCC tissues with independent microarray datasets as well as additional clinical specimens and confirmed that HCC patients with elevated FSTL3 levels are less responsive to immunotherapy compared to patients with reduced FSTL3 levels.